One case of ejection-fraction preserved heart failure combined with hy-pertension and atrial fibrillation was treated with Sacubitril Valsartan and literature review
Sacubitril Valsartan is recommended for adult patients with chronic heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and heart failure hospitalization,and is also used to treat essential hypertension.Guidelines recommending Sacubitril Valsartan for the treatment of heart failure with preserved ejection fraction,and the 2023 hypertension guidelines include Sacubitril Valsartan as a new first-line therapy.However,there is no clear recom-mendation on drug therapy for patients with ejection-fraction preserving heart failure combined with hypertension and atrial fibrillation.A review of the literature has found that Sacubitril Valsartan has a potential effect on the prognosis of these pa-tients.
Ejection fraction retention for heart failureHypertensionAtrial fibrillationSacubitril Valsartan
万方数据
维普
